ArticleNeuro-oncology advances

Erratum: This is a corrigendum to: Kumthekar et al, A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma, Neuro-Oncology Advances, Volume 4, Issue 1, January-December 2022, vdac123, https://doi.org/10.1093/noajnl/vdac123.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.